Legal News

The Centers for Medicare and Medicaid Services has come out with new, less stringent rules on the coverage of two popular anemia drugs. The new rules apply mostly to cancer patients who receive chemotherapy that causes anemia and people with the bone marrow disorder myelodysplasia.

Prosecutors charged Valdes with conspiring with the owners of Med-Pro Billing and Unimed Pharmacy to refer patients to them in exchange for half of what Medicare paid for compounded aerosol medications.

Congress inserted a little-noticed provision into the Iraq war supplemental spending bill, mandating the use of tamper-resistant Rx pads for Medicaid prescriptions not submitted electronically.

FDA and AHRQ heard from pharmacists and others that RiskMAPs have often caused complications in medication dispensing. Current drugs with RiskMAPs include Clozapine, Thalidomide, Lindane and Isotretinoin.

The Food and Drug Administration's "Medication Guide" program, set up nine years ago as a major avenue of informing patients about risks or special issues with certain drugs, has a host of problems, according to pharmacists and other witnesses at a recent hearing.

In proposed legislation that could save millions of taxpayer dollars in drug costs, the U.S. Senate is considering extending current 340B program discounts to include inpatients.

RFID progress still slow; ezScriptWriter for legible Rxs; reducing drug diversion through ImageWare Forensic Medicine Technology; Know Your Number health-risk addessment tool; e-prescriptions grow

The use of intravenous (IV) syringes for non-IV applications such as enteral feedings poses many risks, especially for the pediatric and neonatal population which has a majority of their oral and enteral doses provided through a gastric tube. The Baxa Corporation recently announced the launch of a new educational campaign to make healthcare providers aware of these problems and offer solutions.

The use of intravenous (IV) syringes for non-IV applications such as enteral feedings poses many risks, especially for the pediatric and neonatal population which has a majority of their oral and enteral doses provided through a gastric tube. The Baxa Corporation recently announced the launch of a new educational campaign to make healthcare providers aware of these problems and offer solutions.